Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

188.21 +4.06 (+2.20%)

Streaming Delayed Price Updated: 11:04 AM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Today 7:00 EDT

From Glaukos Corporation

Via Business Wire

Glaukos (GKOS) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

iDose TR drove $74M in Q2 revenue as Glaukos raised full-year guidance.

Via The Motley Fool

Topics Earnings

Glaukos Q2 Earnings Call Highlights ↗

July 30, 2026

Glaukos (NYSE:GKOS) reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth...

Via MarketBeat

Topics Earnings

Glaukos Announces Second Quarter 2026 Financial Results

July 29, 2026

From Glaukos Corporation

Via Business Wire

GKOS (Glaukos Corp) Shows Strong Trend Template Compliance and High Growth Momentum on ChartMill ↗

June 20, 2026

Via Chartmill

Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat ↗

April 29, 2026

Via Chartmill

Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules ↗

April 03, 2026

Via Chartmill

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

July 27, 2026

From Glaukos Corporation

Via Business Wire

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now? ↗

July 14, 2026

Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.

Via The Motley Fool

Topics Regulatory Compliance

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 08, 2026

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Via The Motley Fool

Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗

February 17, 2026

Via Chartmill

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29

July 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

June 25, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in Upcoming Investor Conferences

May 12, 2026

From Glaukos Corporation

Via Business Wire

Glaukos (GKOS) Q1 2026 Earnings Transcript ↗

April 29, 2026

Glaukos (GKOS) Q1 2026 Earnings Transcript

Via The Motley Fool

Glaukos Announces First Quarter 2026 Financial Results

April 29, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces the Release of its 2025 Sustainability Report

April 16, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Receives Permanent J-code for Epioxa™

April 15, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

April 08, 2026

From Glaukos Corporation

Via Business Wire

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 06, 2026

From Glaukos Corporation

Via Business Wire

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

March 19, 2026

From Glaukos Corporation

Via Business Wire

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.

Via The Motley Fool

Topics Regulatory Compliance

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

Glaukos (GKOS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

February 17, 2026

From Glaukos Corporation

Via Business Wire

Director Sells GKOS 15,000 Shares for $1.9 Million ↗

January 31, 2026

This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.

Via The Motley Fool

Topics Regulatory Compliance

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

January 28, 2026

From Glaukos Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.